Business Description
Clinuvel Pharmaceuticals is an Australian medical company that researches and sells treatments for rare and serious genetic conditions, with operations spanning Europe, the United States, Switzerland, and beyond. Its primary approved product, SCENESSE, protects adults with erythropoietic protoporphyria from severe sensitivity to light, while several other treatments are being developed to address neurological, hormonal, and degenerative diseases. The company also offers skin care products designed to help people manage exposure to ultraviolet and high-energy visible light. Founded in 1999 and based in Melbourne, Clinuvel continues to expand its work in the science of melanocortin, a biological pathway with broad medical applications.
